Bonig, Halvard
Verbeek, Mareike
Herhaus, Peter
Braitssch, Krischan
Beutel, Gernot
Schmid, Christoph
Müller, Nadine
Bug, Gesine
Döring, Michaela
von Stackelberg, Arend
Tischer, Johanna
Ayuk, Francis
Wulf, Gerald
Holtick, Udo
Pfeffermann, Lisa-Marie
Jahrsdörfer, Bernd
Schrezenmeier, Hubert
Kuci, Selim
Kuci, Zyrafete
Zens, Anke
Tribanek, Michael
Zeiser, Robert
Huenecke, Sabine
Bader, Peter
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 7 September 2023
Accepted: 13 November 2023
First Online: 21 November 2023
Declarations
:
: This anonymized analysis of data collected for PSUR is exempt from ethics approval.
: Not applicable.
: PB, SK, ZK, and HB have received licensing fees and royalties for MSC-FFM. HB furthermore acknowledges research support from Erydel, Miltenyi, Sandoz-Hexal (a Novartis company); honoraria and speaker fees from Medac, Miltenyi, Novartis and Terumo BCT; consultancy and membership in advisory boards for Boehringer-Ingelheim, Celgene (a BMS company), Medac, Novartis and Sandoz-Hexal; stock ownership in Healthineers. MV declares honoraria from Pfizer, Novartis, Jazz, MSD and Abbvie; travel support from medac, Jazz and Gilead, advisory board in MSD and Abbvie. AZ and MT are employees of medac, licensee of MSC-FFM. RZ is the Principal Investigator of the IDUNN trial and was the Principal Investigator of several ruxolitinib trials, including the pivotal REACH2 study. RZ received speaker fees from Novartis, Incyte, MNK and Sanofi. GB has received honoraria from Novartis, Jazz, BMS, Gilead and Pfizer and travel grants from Jazz, Gilead and Neovii. None of the other authors have any declarations.